OBJECTIVE: To review the safety of simultaneous bilateral posterior cricoarytenoid muscle botulinum toxin injections. DESIGN: Retrospective case series review. SETTING: Tertiary care academic clinic. @entity1 : Twenty-one @entity1 with @entity7364 . INTERVENTIONS: @entity1 received 100 simultaneous bilateral posterior cricoarytenoid muscle botulinum toxin injections for isolated @entity7364 over a 6-year period. MAIN OUTCOME MEASURES: Major and minor complications, injection dosing, and demographics. RESULTS: The total bilateral botulinum toxin injection dose per session ranged from 2.50 to 7.50 U, and the average total bilateral dose per @entity1 was 4.70 U. There were no major complications, and minor complications were self-limited. There was a 5% incidence of significant @entity1353 and a 2% incidence of @entity1282 , and all @entity1 were treated conservatively. The average doses at which @entity1353 and @entity1282 occurred were 4.97 and 5.56 U, respectively. CONCLUSIONS: This case series demonstrates that simultaneous bilateral posterior cricoarytenoid muscle botulinum toxin injection is safe up to the highest doses reported. Complications with this approach are consistent with those previously reported using other methods. Prospective studies on vocal outcome measures are needed for simultaneous bilateral posterior cricoarytenoid muscle botulinum toxin injections to evaluate the efficacy of this technique.

Safety of simultaneous bilateral botulinum toxin injections for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity1353 :: ('MESH:D004417', 'Disease') :: ['dyspnea'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia'] @entity7364 :: ('MESH:D055154', 'Disease') :: ['abductor spasmodic dysphonia']
@entity7364 :: (MESH:D055154,Disease) :: ['abductor spasmodic dysphonia']
